Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
ETNB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.16 - $11.84
Previous Close$6.59
Volume1.55M
Average Volume (3M)1.50M
Market Cap
$1.20B
Enterprise Value$1.03B
Total Cash (Recent Filing)$561.16M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 06, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding148,308,240
10 Day Avg. Volume1,468,580
30 Day Avg. Volume1,498,848
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.23
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue48.90K
Enterprise Value/Gross Profit-57.05K
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$27.00Price Target Upside234.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsETNB's pegozafermin is showing strong progress with reaffirmed clinical data timing in NASH and severe hypertriglyceridemia, indicating a promising trajectory.
Competitive PositionETNB is well-positioned with pegozafermin as a potentially best-in-class compound due to its competitive efficacy profile and differentiation on safety, tolerability, and dosing frequency.
Mechanism ValidationCompelling 96-week results from AKRO’s Phase 2b SYMMETRY trial of efruxifermin in cirrhotic NASH patients provide positive readthrough for ETNB’s ENLIGHTEN-Cirrhosis study, validating the FGF21 mechanism.
Bears Say
Market CompetitionPivotal data from competitors in the severe hypertriglyceridemia treatment landscape could reset clinical and commercial expectations, impacting pegozafermin's adoption.
Market PositioningGreater clarity on pegozafermin’s clinical profile is needed to understand its positioning within the rapidly expanding NASH landscape and the associated commercial opportunity.
Regulatory PathwayThe strong launch of MDGL's Rezdiffra and its potential full approval could have implications on pegozafermin's regulatory pathway, physician prescribing, and access/reimbursement.
89bio News
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $4.16 and its highest was $11.84 in the past 12 months.
What is 89bio’s market cap?
89bio’s market cap is $1.20B.
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Nov 06, 2025 which is in 51 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on Aug 07, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.209.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -0.5.
How many shares outstanding does 89bio have?
89bio has 148,308,240 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 1.552%.
Which hedge fund is a major shareholder of 89bio?
Currently, no hedge funds are holding shares in ETNB
89bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (234.57% Upside)
$27.00 (234.57% Upside)
Blogger Sentiment
Neutral
ETNB Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 501.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.5%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.24%
12-Months-Change
Fundamentals
Return on Equity
-86.86%
Trailing 12-Months
Asset Growth
3.67%
Trailing 12-Months
Company Description
89bio
89bio, Inc. (ETNB) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's core product candidate, pegozafermin, is designed to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Operating primarily within the biotechnology sector, 89bio aims to address the significant unmet medical needs associated with these conditions by advancing its novel therapeutic solutions through clinical trials.
ETNB Stock 12 Month Forecast
Average Price Target
$27.00
▲(234.57% Upside)
Technical Analysis
Spyre Therapeutics
―
Arcus Biosciences
―
Vir Biotechnology
―
Enliven Therapeutics
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
15.01% Insiders
14.64% Mutual Funds
1.65% Other Institutional Investors
56.69% Public Companies and
Individual Investors